Use of interleukin-22 in the treatment of fatty liver disease
The present invention relates to use of interleukin-22 (IL-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of IL-22 in decreasing the levels of transaminases is also provided.
1. A method for treatment of a subject having fatty liver disease, wherein said method comprises administering to the subject in need of treatment a composition, said composition comprises a pharmaceutically effective amount of IL-22.
2. The method according to claim 1 , wherein said IL-22 is human IL-22.
3. The method according to claim 1 , wherein said IL-22 is encoded by the polynucleotide of SEQ ID NO: 1.
4. The method according to claim 1 , wherein said fatty liver disease is alcoholic fatty liver disease.
5. The method according to claim 1 , wherein said composition reduces body weight.
6. The method according to claim 1 , wherein said composition reduces liver weight.
7. The method according to claim 1 , wherein the pharmaceutically effective amount of IL-22 is 10 μg/kg/d-300 μg/kg/d.
8. The method according to claim 1 , wherein the pharmaceutically effective amount of IL-22 is 10 μg/kg/d-100 μg/kg/d.
9. The method according to claim 1 , wherein said fatty liver disease is non-alcoholic fatty liver disease.
10. The method according to claim 1 , wherein said IL-22 is fused to an Fc.
11. The method according to claim 10 , wherein said IL-22 is fused to the N-terminus of the Fc.
12. The method according to claim 10 , wherein said IL-22 is fused to the C-terminus of the Fc.